New pill targets Hard-to-Treat cancers after other drugs fail

NCT ID NCT05241834

Ongoing Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-stage trial is testing an oral drug called LOXO-260 in about 70 people with advanced cancers that have a specific change in the RET gene. The cancers have stopped responding to other targeted treatments. The study aims to find the safest dose and see if the drug can shrink tumors. Participation may last up to 2 years or longer if the disease does not worsen.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LOXO-260 (oral drug)
What this could lead to: If it works, this could provide a new treatment option for people with certain cancers that have stopped responding to other targeted therapies.
What could go wrong: This is an early, small Phase 1 trial focused on safety and dosing, so it is not yet clear if LOXO-260 will be effective. Side effects are unknown and the drug may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

medullary thyroid gland carcinoma multiple endocrine neoplasia type 2 non-small cell lung carcinoma RET fusion positive cancer Thyroid Neoplasms thyroid tumor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARCINOMA, NON-SMALL-CELL LUNG THYROID NEOPLASMS

Contacts and locations

Locations

Centre Leon Berard

Lyon, 69008, France
Cleveland Clinic Foundation

Cleveland, Ohio, 44195, United States
Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Emory University

Atlanta, Georgia, 30329-5102, United States
Institut Gustave Roussy (Igr)

Villejuif, 94805, France
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Ohio State University Hospital

Columbus, Ohio, 43210-1257, United States
Sarah Cannon Cancer Center

Nashville, Tennessee, 37203, United States
Thomas Jefferson University

Philadelphia, Pennsylvania, 19107, United States
UCLA Medical Center

Los Angeles, California, 90095, United States
UCSF Medical Center at Mission Bay

San Francisco, California, 94158, United States
University of Chicago Medicine-Comprehensive Cancer Center

Chicago, Illinois, 60637, United States
University of Michigan

Ann Arbor, Michigan, 48109, United States
University of North Carolina

Chapel Hill, North Carolina, 27514, United States
University of Texas MD Anderson Cancer Center

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.